Stereotaxis Ord - STXS STOCK NEWS

Stereotaxis (NYSE: STXS) announced it will showcase the first-ever live demonstration of its GenesisX Robotic System at the Heart Rhythm Symposium (HRS) in San Diego from April 24-27, 2025. The GenesisX system represents a significant advancement in endovascular surgical robotics, featuring a compact design with built-in magnetic shielding and 80% smaller system cabinet that fits under operating room tables.

The system operates on standard power, requires no structural anchoring, and maintains high performance standards. GenesisX received CE Mark approval in Europe in 2024 and is currently under FDA 510(k) review. The company will also display its portfolio of compatible catheters including Map-iT™, MAGiC™, and EMAGIN™, alongside Synchrony™ and SynX™ digital lab technologies.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has been highlighted at NVIDIA's GTC artificial intelligence conference and accepted into the NVIDIA Connect program. The conference, attended by over 25,000 participants in San Jose, featured Stereotaxis' surgical robots during NVIDIA's VP of Healthcare and Life Sciences' special address.

Stereotaxis' robotic technologies have been utilized in over 150,000 patient treatments across more than 100 leading hospitals globally. The company is now focusing on digital solutions incorporating artificial intelligence, robotic automation, data integration, and decision support capabilities to enhance its robotic systems and operating room environment.

Through the NVIDIA Connect program membership, Stereotaxis gains access to NVIDIA's software development resources, frameworks, and development kits to support its technological advancement initiatives.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced its participation in the 37th Annual ROTH Conference in Dana Point, California. Chairman and CEO David Fischel will be available for one-on-one meetings on March 17th, 2025.

The company's innovative technology has been utilized to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis specializes in developing robotic systems, instruments, and information solutions for the interventional laboratory, focusing on enhancing physician capabilities through robotic precision and safety, while expanding access to minimally invasive therapy and improving operating room productivity and connectivity.

Stereotaxis (NYSE: STXS) has submitted an FDA 510(k) application for its EMAGIN™ 5F catheter, the first robotically navigated catheter designed to expand Robotic Magnetic Navigation into broader endovascular applications. The device is a 5-French diameter catheter guide for navigating complex venous and arterial vasculature.

The EMAGIN brand will include a comprehensive portfolio of robotic catheters and wires, targeting treatments for stroke, cancer, and cardiovascular disease. The company plans to submit for European CE Mark clearance this month and anticipates launching EMAGIN 5F in the second half of 2025 following regulatory approvals.

The catheter is manufactured by Stereotaxis' fully-owned subsidiary Access Point Technologies in Minnesota. The technology aims to enable efficient and safe navigation to difficult-to-reach vascular anatomy, with potential applications in interventional cardiology, radiology, and neurology.

Stereotaxis (NYSE: STXS) has submitted its MAGiC Sweep™ catheter for FDA regulatory clearance, marking a significant milestone as the first high-density EP mapping catheter designed for robotic navigation using Stereotaxis' Robotic Magnetic Navigation systems.

The innovative catheter offers several advantages: rapid electroanatomical mapping from 20 electrodes simultaneously, enhanced safety through atraumatic design, improved access to difficult heart areas, better robotic workflow, and more accurate anatomical mapping. The company plans to submit for European CE Mark clearance this month.

MAGiC Sweep, designed and manufactured by Stereotaxis' subsidiary Access Point Technologies in Minnesota, is expected to launch commercially in the second half of 2025 following anticipated approvals. This development represents the first dedicated diagnostic catheter for Stereotaxis' robotic technology, complementing their existing robotic ablation catheter innovations.

Stereotaxis (NYSE: STXS) reported Q4 2024 financial results with revenue of $6.3 million, up 39% year-over-year. Full-year 2024 revenue reached $26.9 million compared to $26.8 million in 2023.

Q4 breakdown shows system revenue of $1.4 million and recurring revenue of $4.9 million. The company maintains a system backlog of $15.2 million entering 2025. Gross margins were 51% for Q4 and 54% for the full year, with recurring revenue margins at 70% and system revenue at 20%.

The company achieved several milestones including European approval of MAGiC catheter, first GenesisX robot sale, and Chinese regulatory approvals for Genesis and Magbot. Q4 saw positive cash flow of $1.3 million, ending 2024 with $12.4 million cash and no debt.

For 2025, Stereotaxis projects double-digit revenue growth with recurring revenue expected to scale from $5 million in Q1 to $7 million in Q4. System revenue is forecast at $2-3 million per quarter.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts. Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.

Stereotaxis is focused on the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Their innovations help physicians provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance productivity in operating rooms. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET the same day.

Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 1983976. A webcast will be available through the investor relations section of Stereotaxis' website, and a phone replay will be accessible for one month after the call.

The company's technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Stereotaxis (NYSE: STXS) has received its first order for the GenesisX™ robotic system from a European hospital. GenesisX represents the latest advancement in endovascular surgical robotics, featuring smaller magnets and built-in magnetic shielding, eliminating the need for wall shielding installation.

The system operates on standard power outlets without requiring structural floor anchoring. It includes a cabinet 80% smaller than previous versions and can be stored under an operating room table. The system maintains high performance standards while being more compact and lighter than previous generations.

GenesisX received CE Mark in Europe in 2024 and is pending FDA 510(k) clearance in the US. Throughout 2025, Stereotaxis plans to obtain regulatory approvals for compatible catheters, demonstrate real-world usage, enhance x-ray compatibility, and prepare for full commercial launch.